Eyewire News

Featured Story

EyePoint to Cut Workforce Following Phase 3 Duravyu Results image

10.20.2026

EyePoint to Shift Focus, Cut Workforce Following Phase 3 Duravyu Results

EyePoint announced plans to reduce its workforce by approximately 53% and end its phase 3 wet age-related macular degeneration (AMD) trials early after its investigational therapy Duravyu (vorolanib intravitreal insert) failed to meet the primary endpoint in a second pivotal phase 3 study. The restructuring, announced on Monday, is expected to generate approximately $30 million in annualized savings as the company shifts resources toward its late-stage Duravyu program in diabetic macular edema (DME).

Read Story

Latest News Stories

10.20.2026

Envision and VisionServe Alliance Announce 2027 National Conference in Houston

10.20.2026

RxSight Appoints Taryn Conway, Frank Shields to Commercial Leadership Positions

Second Phase 3 Trial of Duravyu in Wet AMD Misses Primary Endpoint image

10.19.2026

Second Phase 3 Trial of Duravyu in Wet AMD Misses Primary Endpoint

FDA Approves Ryzumvi for the Treatment of Presbyopia image

10.19.2026

FDA Approves Ryzumvi for the Treatment of Presbyopia

SpyGlass Pharma Announces Positive 4-Year Data for BIM-IOL System image

10.19.2026

SpyGlass Pharma Announces Positive 4-Year Data for BIM-IOL System

Prevent Blindness Declares October 19-25 as Annual Inflammatory Eye Disease Week image

10.19.2026

Prevent Blindness Declares October 19-25 as Annual Inflammatory Eye Disease Week

FDA Approves Alcon’s Brytly Redness Reliever Eye Drops image

10.19.2026

FDA Approves Alcon’s Brytly Redness Reliever Eye Drops

10.19.2026

Oculis Completes Randomization for its Phase 2 Trial of Licaminlimab

10.16.2026

Alvotech and Advanz Pharma Submit European Application for First Proposed Eylea 8 mg Biosimilar

International Eye Health Organizations Call for Global Support of St John's Compact Ahead of 2026 Summit image

10.16.2026

International Eye Health Organizations Call for Global Support of St John's Compact Ahead of 2026 Summit

10.16.2026

FDA Approves Genentech's Enspryng as First At-Home Subcutaneous Treatment for Thyroid Eye Disease

10.15.2026

Study Finds Rising Demand for Emergency Ophthalmology Consultations Across US Academic Centers

Raytracing-Guided LASIK Improves Visual Outcomes in Patients Dissatisfied after Cataract Surgery image

10.15.2026

Raytracing-Guided LASIK Improves Visual Outcomes in Patients Dissatisfied after Cataract Surgery

Eclipse Life Sciences Reports Positive Phase 2 Results for EC-104 in DME image

10.15.2026

Eclipse Life Sciences Reports Positive Phase 2 Results for EC-104 in DME

European Trial Finds PRIMA Retinal Implant Demonstrates Sustained Vision Improvement at 3 Years in GA image

10.14.2026

European Trial Finds PRIMA Retinal Implant Demonstrates Sustained Vision Improvement at 3 Years in GA

Cosmetic Products Linked to More than 42,000 Eye Injuries Over 20 Years, Study Finds image

10.14.2026

Cosmetic Products Linked to More than 42,000 Eye Injuries Over 20 Years, Study Finds

Euclid Vision Launches My Euclid Platform to Streamline Orthokeratology Fitting and Ordering image

10.14.2026

Euclid Vision Launches My Euclid Platform to Streamline Orthokeratology Fitting and Ordering

10.12.2026

ANI Pharmaceuticals Reports Sustained 24-Month Efficacy of Iluvien in Phase 4 SYNCHRONICITY Trial

10.12.2026

Merck’s Remigromig Meets Primary Endpoint in Phase 2b/3 BRUNELLO Trial for DME

View More

EyewireTV

Eyewire TV October 14, 2026 thumbnail

10.14.2026

The Latest EyewireTV

Alcon Unity M

Zeiss HMDmd CR3

J&J Smartload Delivery Technology

Watch Episode

Watch the Latest Episode

Stay Updated

Sign up for Eyewire News and EyewireTV e‑newsletters to stay up to date on news in eye care!

Subscribe